Cargando…

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

BACKGROUND: Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira-Hermosillo, Aldo, Molina-Ayala, Mario Antonio, Molina-Guerrero, Diana, Garrido-Mendoza, Ana Pamela, Ramírez-Rentería, Claudia, Mendoza-Zubieta, Victoria, Espinosa, Etual, Mercado, Moisés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023779/ https://www.ncbi.nlm.nih.gov/pubmed/32059692 http://dx.doi.org/10.1186/s13063-020-4121-x

Ejemplares similares

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2014)

High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT)
por: Mendoza-Zubieta, Victoria, et al.
Publicado: (2015)

Gastroesophageal reflux disease in patients with long standing type 1 diabetes mellitus: utility of two self-report questionnaires in a multifactorial disease
por: Valdez-Solis, Emmanuel Marin, et al.
Publicado: (2017)

Are there really any predictive factors for a successful weight loss after bariatric surgery?
por: Cadena-Obando, Diego, et al.
Publicado: (2020)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2015)

Clinical Characteristics and Treatment Outcome of 485 Patients with Nonfunctioning Pituitary Macroadenomas
por: Vargas, Guadalupe, et al.
Publicado: (2015)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications
por: García-Sáenz, Manuel, et al.
Publicado: (2022)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker, Catherine M, et al.
Publicado: (2016)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Symptomatic Primary Hyperparathyroidism as a Risk Factor for Differentiated Thyroid Cancer
por: Vargas-Ortega, Guadalupe, et al.
Publicado: (2018)

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
por: Caturano, Alfredo, et al.
Publicado: (2023)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

A Rare Presentation of Primary Hyperparathyroidism with Concurrent Aldosterone-Producing Adrenal Carcinoma
por: Molina-Ayala, Mario, et al.
Publicado: (2015)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Effect of Human Adenovirus 36 on Response to Metformin Monotherapy in Obese Mexican Patients with Type 2 Diabetes: A Prospective Cohort Study
por: Tapia-Rivera, José Carlos, et al.
Publicado: (2023)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients
por: Firouzjaei, A, et al.
Publicado: (2016)

Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality
por: Tizazu, Anteneh Mehari, et al.
Publicado: (2019)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
por: Akram, Ayesha
Publicado: (2021)

Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise
por: Nian, Hua, et al.
Publicado: (2020)

Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach
por: Satyam, Shakta Mani, et al.
Publicado: (2023)

FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control
por: Phadke, Dr Uday, et al.
Publicado: (2023)

Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves’ disease: a case report
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2018)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients
por: Ortega-Ayala, Adiel, et al.
Publicado: (2022)

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
por: Chin, Ken Lee, et al.
Publicado: (2019)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_07398467d9al928f82223k4bps